Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Interview: East vs. West – Is there a regional approach to PPM in the US?
Read the full interview with Leigh Shultz, PhD, PMP, Associate Vice President, Project Management – Primary Care, Infectious Disease, Vaccines, Global Project & Alliance Management, Merck and gain insight into the regional approach to PPM across the US.
1. What are the main differences in (pharma/biopharma) PPM between East and West cost of US?
The differences are not clear to me. We all work in the same business – many large pharma are now bi-coastal, and the biopharma culture on the west coast is now being replicated in Boston, for example. This should be cutting down on regionalization or differences, and yet the two PM communities don’t operate as one for some reason.
2. What are the tendencies? Are we heading to unification?
There is a perception that the west coast is more bio-pharma rather than traditional big pharma or more innovative/entrepreneurial. I think this may just be a perception, but the perception may be enough to influence the process mindset and project management approach in the companies.
3. How can the size of a company influence PPM strategies across more regions?
This depends on both the size of the company, its footprint, and its approach. For R&D PM, it depends more on where R&D is located and the size of the portfolio than size of the company per se.
4. What is the standpoint of Merck to regional differences in PPM strategies?
Merck’s R&D PM expertise is located in HQ in the US northeast, and we tend to be active in networking with other PM organizations in our region. We would like to make this a more global PM community – at a minimum, looking at approaches and opening dialogue across the industry in the US, regardless of region. It’s not clear why barriers might exist – perception only, time differences, culture, company size…?
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.